Trials / Completed
CompletedNCT01235936
Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia
Phase 2a Open-Label Pilot Study to Assess the Pharmacodynamic Response, Pharmacokinetics, Safety, and Tolerability of 28-Day Repeat Oral Doses of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), Stages 3 and/or 4
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Akebia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, pharmacodynamics and pharmacokinetics of repeat doses of orally administered AKB-6548 in pre-dialysis participants with anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AKB-6548 | Different dose levels |
Timeline
- Start date
- 2010-10-21
- Primary completion
- 2011-04-13
- Completion
- 2011-05-01
- First posted
- 2010-11-08
- Last updated
- 2022-07-01
- Results posted
- 2022-07-01
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01235936. Inclusion in this directory is not an endorsement.